Here are Deepak Shenoy's few trading ideas

Watch the interview of Deepak Shenoy of capitalmind.in with Latha Venkatesh and Ekta Batra on CNBC-TV18, in which he shared his readings and outlook on the market, specific stocks and sectors.Below is the verbatim transcript of Deepak Shenoy's interview with CNBC-TV18Larsen & Toubro"We are invested in Larsen & Toubro (L&T) for a long time. The issues with L&T that have cropped up recently are issues about two of its toll ways that have not realised; one of them has not realised as much toll as it should have because in Gujarat we praise the road network so much and what has happened is that there are alternative routes instead of taking the toll way and that has hurt their earnings. In that context the special purpose vehicle (SPV) that was created was not able to meet its financial commitment. It has not been able to for the last two years and L&T has been filling the gap." "This time L&T decided not to fill the gap but, after six days it paid up. So there is no default currently. It is just that the bonds have been downgraded to default and they are not moving it back up even though the payment has been made six days later. L&T does not have any obligation to pay up. These are SPVs that are protected. They are not something that L&T have any obligation or do have any guarantee to need to pay. So that is one thing that needs to be noted," he said. "However, same thing with Chennai- Tata expressway where they have not received about 10 percent right of way, so the land acquisition has not happened and since 2009 that has been stalled while the expressway continues to collect lot of toll. They aren't able to commission and use their part of the agreement. So in that context these defaults are small, they are controlled but L&T's exposure. They have Rs 200 crore plus exposure that they will lose if the assets are obtained by the lenders in case of a default. So there is a constellation on what is happening in terms of rating but in a way L&T is protected because of the SPV structure but it does stand to lose equity.""In that context we like the stock. In general we see that this may just be the beginning and there will be lot more that will come in terms of headwinds from more of such toll ways going under pressure," he added.Pharma"The rupee is at 66 or 65 to the dollar and that is going to obviously benefit companies in the pharmaceutical space. We are long in number of pharmaceutical companies and one of them which we have recently added is Cadila Healthcare largely because two triggers. The stock spread is coming up and the adding into futures and options and its results have been phenomenal in the last quarter. We expect pretty good results going forward as well. We think that the overall positive tailwinds in a way for the pharmaceutical space will impact the stock. We are positive on Sun Pharmaceutical Industries and Strides Arcolab as well.""One of the things is that when Food and Drug Administration (FDA) process happens we get a lot of shocks. So, the thing that happens in pharmaceuticals is that it becomes a little bit of a lumpy thing. If the FDA approval comes, the stocks go up a lot. If they do not come or the FDA raises an objection, they fall. These companies will eventually pass over. In fact, Sun Pharma has a major problem after the Ranbaxy acquisition to get its plans FDA approved. But, we believe that in the longer-term they will tide over these problems and will fix them. It will cost them certain amount of money to fix the problem that they have, but once they do, they will be a significant player," he said."Some of the former hedge fund manager just bought a drug which was costing USD 15 a tablet and raised its price to USD 750. This drug is available for Rs 3 in India from Lupin, Torrent Pharma and a couple of other companies. So, if this space opens out and America is trying to say that we cannot have these kind of expensive drugs moving out anymore, it will only benefit Indian generic companies. That will benefit our pharmaceutical space which is very heavy on generics. So, while the FDA issue is a challenge, we also have something positive there," he added.